SEARCH

SEARCH BY CITATION

References

  • 1
    Stevenson EK, Rubenstein AR, Radin GT, Wiener RS, Walkey AJ. Two decades of mortality trends among patients with severe sepsis: a comparative meta-analysis. Crit Care Med 2013.
  • 2
    Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003: 348 (2): 13850.
  • 3
    Christaki E, Anyfanti P, Opal SM. Immunomodulatory therapy for sepsis: an update. Expert Rev Anti Infect Ther 2011: 9 (11): 101333.
  • 4
    Gogos C, Kotsaki A, Pelekanou A et al. Early alterations of the innate and adaptive immune statuses in sepsis according to the type of underlying infection. Crit Care 2010: 14 (3): R96.
  • 5
    Poukoulidou T, Spyridaki A, Mihailidou I et al. TREM-1 expression on neutrophils and monocytes of septic patients: relation to the underlying infection and the implicated pathogen. BMC Infect Dis 2011: 11: 309.
  • 6
    Ferwerda B, McCall MB, Alonso S et al. TLR4 polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humans. Proc Natl Acad Sci U S A 2007: 104 (42): 1664550.
  • 7
    Waterer GW, Quasney MW, Cantor RM, Wunderink RG. Septic shock and respiratory failure in community-acquired pneumonia have different TNF polymorphism associations. Am J Respir Crit Care Med 2001: 163 (7): 1599604.
  • 8
    Gallagher PM, Lowe G, Fitzgerald T et al. Association of IL-10 polymorphism with severity of illness in community acquired pneumonia. Thorax 2003: 58 (2): 1546.
  • 9
    Tang GJ, Huang SL, Yien HW et al. Tumor necrosis factor gene polymorphism and septic shock in surgical infection. Crit Care Med 2000: 28 (8): 27336.
  • 10
    O'Keefe GE, Hybki DL, Munford RS. The G>A single nucleotide polymorphism at the −308 position in the tumor necrosis factor-alpha promoter increases the risk for severe sepsis after trauma. J Trauma 2002: 52 (5): 81725 discussion 825–6.
  • 11
    Barber RC, Aragaki CC, Rivera-Chavez FA, Purdue GF, Hunt JL, Horton JW. TLR4 and TNF-alpha polymorphisms are associated with an increased risk for severe sepsis following burn injury. J Med Genet 2004: 41 (11): 80813.
  • 12
    Kotsaki A, Raftogiannis M, Routsi C et al. Genetic polymorphisms within tumor necrosis factor gene promoter region: a role for susceptibility to ventilator-associated pneumonia. Cytokine 2012: 59 (2): 35863.
  • 13
    Watanabe E, Zehnbauer BA, Oda S, Sato Y, Hirasawa H, Buchman TG. Tumor necrosis factor −308 polymorphism (rs1800629) is associated with mortality and ventilator duration in 1057 Caucasian patients. Cytokine 2012: 60 (1): 24956.
  • 14
    Azevedo ZM, Moore DB, Lima FC et al. Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) single nucleotide polymorphisms: importance in ARDS in septic pediatric critically ill patients. Hum Immunol 2012: 73 (6): 6617.
  • 15
    Thompson CM, Holden TD, Rona G et al. Toll-like receptor 1 polymorphisms and associated outcomes in sepsis after traumatic injury: a candidate gene association study. Ann Surg 2014: 259 (1): 17985.
  • 16
    Pino-Yanes M, Corrales A, Casula M et al. Common variants of TLR1 associate with organ dysfunction and sustained pro-inflammatory responses during sepsis. PLoS One 2010: 5 (10): e13759.
  • 17
    Wurfel MM, Gordon AC, Holden TD et al. Toll-like receptor 1 polymorphisms affect innate immune responses and outcomes in sepsis. Am J Respir Crit Care Med 2008: 178 (7): 71020.
  • 18
    Khor CC, Chapman SJ, Vannberg FO et al. A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat Genet 2007: 39 (4): 5238.
  • 19
    Lehmann LE, Book M, Hartmann W et al. A MIF haplotype is associated with the outcome of patients with severe sepsis: a case control study. J Transl Med 2009: 7: 100.
  • 20
    Yende S, Angus DC, Kong L et al. The influence of macrophage migration inhibitory factor gene polymorphisms on outcome from community-acquired pneumonia. FASEB J 2009: 23 (8): 240311.
  • 21
    Li L, Nie W, Zhou H, Yuan W, Li W, Huang W. Association between plasminogen activator inhibitor-1-675 4G/5G polymorphism and sepsis: a meta-analysis. PLoS One 2013: 8 (1): e54883.
  • 22
    Morelli A, Ertmer C, Westphal M et al. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA 2013: 310 (16): 168391.
  • 23
    Nakada TA, Russell JA, Boyd JH et al. Beta2-Adrenergic receptor gene polymorphism is associated with mortality in septic shock. Am J Respir Crit Care Med 2010: 181 (2): 1439.
  • 24
    Tang BM, Huang SJ, McLean AS. Genome-wide transcription profiling of human sepsis: a systematic review. Crit Care 2010: 14 (6): R237.
  • 25
    Reinhart K, Bauer M, Riedemann NC, Hartog CS. New approaches to sepsis: molecular diagnostics and biomarkers. Clin Microbiol Rev 2012: 25 (4): 60934.
  • 26
    Gibot S, Bene MC, Noel R et al. Combination biomarkers to diagnose sepsis in the critically ill patient. Am J Respir Crit Care Med 2012: 186 (1): 6571.
  • 27
    Tang BM, McLean AS, Dawes IW, Huang SJ, Lin RC. Gene-expression profiling of peripheral blood mononuclear cells in sepsis. Crit Care Med 2009: 37 (3): 8828.
  • 28
    Johnson SB, Lissauer M, Bochicchio GV, Moore R, Cross AS, Scalea TM. Gene expression profiles differentiate between sterile SIRS and early sepsis. Ann Surg 2007: 245 (4): 61121.
  • 29
    Sutherland A, Thomas M, Brandon RA et al. Development and validation of a novel molecular biomarker diagnostic test for the early detection of sepsis. Crit Care 2011: 15 (3): R149.
  • 30
    Wong HR, Cvijanovich NZ, Allen GL et al. Validation of a gene expression-based subclassification strategy for pediatric septic shock. Crit Care Med 2011: 39 (11): 25117.
  • 31
    Su L, Cao L, Zhou R et al. Identification of novel biomarkers for sepsis prognosis via urinary proteomic analysis using iTRAQ labeling and 2D-LC-MS/MS. PLoS One 2013: 8 (1): e54237.
  • 32
    Paugam-Burtz C, Albuquerque M, Baron G et al. Plasma proteome to look for diagnostic biomarkers of early bacterial sepsis after liver transplantation: a preliminary study. Anesthesiology 2010: 112 (4): 92635.
  • 33
    Ng PC, Ang IL, Chiu RW et al. Host-response biomarkers for diagnosis of late-onset septicemia and necrotizing enterocolitis in preterm infants. J Clin Invest 2010: 120 (8): 29893000.
  • 34
    Schmerler D, Neugebauer S, Ludewig K, Bremer-Streck S, Brunkhorst FM, Kiehntopf M. Targeted metabolomics for discrimination of systemic inflammatory disorders in critically ill patients. J Lipid Res 2012: 53 (7): 136975.
  • 35
    LaRosa SP, Opal SM. Biomarkers: the future. Crit Care Clin 2011: 27 (2): 40719.
  • 36
    Fontana JM, Alexander E, Salvatore M. Translational research in infectious disease: current paradigms and challenges ahead. Transl Res 2012: 159 (6): 43053.
  • 37
    Rapin N, Lund O, Bernaschi M, Castiglione F. Computational immunology meets bioinformatics: the use of prediction tools for molecular binding in the simulation of the immune system. PLoS One 2010: 5 (4): e9862.
  • 38
    Kumar A, Roberts D, Wood KE et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006: 34 (6): 158996.
  • 39
    Savva A, Kanni T, Damoraki G et al. Impact of Toll-like receptor-4 and tumour necrosis factor gene polymorphisms in patients with hidradenitis suppurativa. Br J Dermatol 2013: 168 (2): 3117.
  • 40
    Spyridaki A, Raftogiannis M, Antonopoulou A et al. Effect of clarithromycin in inflammatory markers of patients with ventilator-associated pneumonia and sepsis caused by Gram-negative bacteria: results from a randomized clinical study. Antimicrob Agents Chemother 2012: 56 (7): 381925.
  • 41
    Docke WD, Randow F, Syrbe U et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 1997: 3 (6): 67881.
  • 42
    Meisel C, Schefold JC, Pschowski R et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med 2009: 180 (7): 6408.
  • 43
    Remmelts HH, Meijvis SC, Heijligenberg R et al. Biomarkers define the clinical response to dexamethasone in community-acquired pneumonia. J Infect 2012: 65 (1): 2531.
  • 44
    Bouadma L, Luyt CE, Tubach F et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010: 375 (9713): 46374.
  • 45
    Dellinger RP, Levy MM, Rhodes A et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013: 41 (2): 580637.
  • 46
    Giamarellos-Bourboulis EJ, Pechere JC, Routsi C et al. Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. Clin Infect Dis 2008: 46 (8): 115764.
  • 47
    Giamarellos-Bourboulis EJ, Mylona V, Antonopoulou A et al. Effect of clarithromycin in patients with suspected Gram-negative sepsis: results of a randomized controlled trial. J Antimicrob Chemother 2013.